Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,281 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 24
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 17 more

Conditions: Immuno-Deficiency, COVID-19
Interventions: Evusheld; Drug
Lead sponsor: Ghady Haidar; Other
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Surgical Site Infection, Breast Reconstruction, Antibiotic Use
Interventions: Single pre-operative dose of intravenous antibiotics with intraoperative redosing, One week of post-operative antibiotics; Drug
Lead sponsor: The Plastic Surgery Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Internet-based tailored prevention messages, Non-tailored messages; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID-19, Viral Respiratory Illnesses
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Huntington Beach, California • Long Beach, California + 21 more

Conditions: Hiv, Adolescent Behavior, Family Relations, Sexual Orientation
Interventions: MySTYLE, Waitlist Control; Behavioral · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 14 Years to 20 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: HIV/AIDS, HIV Prevention
Interventions: Tenofovir Douche; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 24 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Chapel Hill, North Carolina

Conditions: Prophylaxis, Stem Cell Transplant Complications
Interventions: Levofloxacin, Ciprofloxacin; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Kidney Disease
Interventions: HEPLISAV, Engerix-B; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: COVID-19
Interventions: Hydroxychloroquine, Placebo oral tablet; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 18 Years and older
Enrollment: 1,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more

Conditions: Covid19, Health Behavior
Interventions: Sm-EMA; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Peer HIV Education Program; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,610 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Saint Davids, Pennsylvania

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Unsupervised Decolonization, Supervised Decolonization; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 6 Months and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: COVID-19
Interventions: ADG20, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 2,582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 60 more

Conditions: HIV/AIDS
Interventions: JIC; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 14 Years to 22 Years
Enrollment: 8,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Catheter-Associated Urinary Tract Infection
Interventions: Nitrofurantoin 100 MG, Placebo Oral Tablet; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: HIV
Interventions: computer-based HIV, STD & Hepatitis Education, educator-delivered HIV, STD and Hepatitis education; Procedure
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 13 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Syphilis, Gonorrhea, Chlamydia Infections, HIV Infections
Interventions: HoMBReS: A lay health advisor approach to STD prevention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Post-Op Infection
Interventions: Metronidazole Vaginal; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: New York, New York • Valhalla, New York

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Search by objective public record fields.

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

PREP (Pre-Exposure Prophylaxis) of COVID-19

Surgical Site Infection and Antibiotic Use Study

A Tailored Interactive Website for Promoting Condom Use Among Young Adults

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

COVID-19 Preventive Behavior in African Americans

A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community

Evaluation of ADG20 for the Prevention of COVID-19

Assessing the Impact of an Educational HIV Prevention Intervention in Zambia

Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery

Computer-Assisted HIV Prevention for Young Drug Users

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

Lay Health Advisors for Sexually Transmitted Disease Prevention

PROJECT PREVENT: Metronidazole Antibiotic Per Vagina Before Hysterectomy: Is Additional Antibiotic Prophylaxis Beneficial?

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults